Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ LEARNING POINTS: Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by COVID-19 CRS can be life-threatening in severe COVID-19 Tocilizumab may have a role in treating severe COVID-19 patients with CRS